瑞舒伐他汀对心律失常合并急性冠状动脉综合征患者超敏C反应蛋白及脂蛋白(a)水平的影响  

Effect of Rosuvastatin on the Levels of High-sensitivity C-reactive Protein and Lipoprotein(a) in Patients with Arrhythmia Complicated with Acute Coronary Syndrome

作　　者：梁魏昉[1] LIANG Wei-fang(Department of Cardiology,The People's Hospital of Anyang City,Anyang Henan 455000,China)

机构地区：[1]安阳市人民医院心内科,河南安阳455000

出　　处：《药品评价》2018年第13期45-47,51,共4页Drug Evaluation

摘　　要：目的:探讨瑞舒伐他汀对心律失常合并急性冠状动脉综合征患者超敏C反应蛋白及脂蛋白(a)水平的影响。方法:随机分配122例患者为对照组(n=61)和观察组(n=61),均给予经皮冠状动脉介入治疗(PCI)等常规治疗,术后,对照组给予阿托伐他汀治疗,观察组同对照组时间给予瑞舒伐他汀治疗,观察两组疗效。结果:两组患者治疗后的SDNN、r MSSD较治疗后明显加快(P<0.05),PNN50较治疗前明显提高,观察组改善效果较对照组更佳(P<0.05);两组患者治疗后的血清hs-CRP、Lp-PLA2及TNF-α较治疗前明显降低(P<0.05),观察组下降幅度较对照组更显著(P<0.05);与治疗前相比,两组患者治疗后的血清Lp(a)、ox-LDL明显降低(P<0.05),观察组改善幅度较对照组更显著(P<0.05);观察组和对照组的不良反应发生率分别为4.92%和6.56%(P>0.05),心血管不良事件发生率分别为3.28%和13.11%(P<0.05)。结论:瑞舒伐他汀治疗ACS合并心律失常患者,可减轻其炎症反应,纠正氧化应激反应,利于心肌功能改善,降低诱发心血管不良事件风险,临床应用安全、有效。Objective:To investigate the effects of rosuvastatin on the levels of high-sensitivity C-reactive protein and lipoprotein(a)in patients with arrhythmia complicated with acute coronary syndrome.Methods:122 patients were randomly assigned to control group(n=61)and observation group(n=61).All patients were given conventional treatment such as percutaneous coronary intervention(PCI).After the operation,the control group was treated with atorvastatin.The observation group was given rosuvastatin for the same time as the control group,and the efficacy of the two groups was observed.Results:The SDNN and rMSSD after treatment in both groups were significantly faster than those after treatment(P<0.05).The PNN50 was significantly higher than before treatment.The improvement effect in the observation group was better than that in the control group(P<0.05);Serum hs-CRP,Lp-PLA2,and TNF-αlevels were significantly lower than before treatment(P<0.05),and the decline in the observation group was more significant than that in the control group(P<0.05);after treatment,both groups were treated Serum Lp(a)and ox-LDL levels were significantly lower(P<0.05).The improvement rate in the observation group was more significant than that in the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group was 4.92%and 6.56%,respectively(P>0.05).The incidence of cardiovascular adverse events was 3.28%and 13.11%,respectively(P<0.05).Conclusion:Rosuvastatin in the treatment of patients with ACS complicated with arrhythmia can reduce its inflammatory response,correct oxidative stress response,improve myocardial function,reduce the risk of cardiovascular adverse events;therefore,clinical application is safe and effective.

关 键 词：瑞舒伐他汀 心律失常合并急性冠状动脉综合征 超敏C反应蛋白 脂蛋白(a) 

分 类 号：R972.6[医药卫生—药品]